Thu, Nov 27, 2014, 12:44 PM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • Ed_Atlanta Ed_Atlanta Apr 26, 1998 12:02 AM Flag

    Onxx - Technical data

    A close above $8 1/4 targets near-term test of $9 1/2. Lehman has a target of $25 for Onxx. I think test of $14 to $16 likely maybe even before ASCO (American Society for Clinical Oncology.

    Any good news on ONYX-015 and $21 to $25 by the end of May. Good luck guys. I like Onxx..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I've followed ENMD stock for about a year now and
      was planning to invest when I got some more cash this
      fall. The interesting thing is that the news is not
      really new. Scientists have known about these data for
      months. Now there's talk of a "Cure" for cancer. Thre
      will never be one cure for cancer. ONXX has a very
      good lead compound and a reasonable pipeline, with
      plenty of corporate support. All it needs is a front
      page Wall Street Journal article and you have another
      ENMD (or something close).

    • Wish I had borrowed to invest in ENMD; you're right for ONXX. Same thing can happen.

    • Dear Felled:
      Where the heck were you before
      today. I was very well aware of Dr. Folkman's work since
      Jan 1997, but I never knew that a company had aquired
      the rights to the distribution. The last that I had
      heard, from Dr. Folkman's office, was that clinical
      trials for TNP-470 were being held at 30 hospitals back
      in March 1997. At that time, a company called TAP
      Pharmaceuticals was supervising the trials. I never was able to
      find out more about that company other than that they
      were located in Deerfield, Illinois. I assumed that it
      was a private company. The next thing I heard about
      any company having an interest in this was YESTERDAY,
      when Entremed went up 40 points on the stock market,
      and every news agency was reporting a "cure" for
      cancer. I'm sure that these reports are somewhat
      premature, but had I known about Entremed's interest, I
      surely would have invested in that company. WHERE WERE
      YOU WHEN I NEEDED YOU????? Just kidding, I'm just
      frustrated that I didn't and currently don't own any
      Entremed stock. Thanks and good luck and God bless.
      JM

    • of what NEWS can do for a BIOTECH. $12 last friday---current price is What????????? THEREFORE regarding ONXX anticipate the news.

    • I believe (though not positive without doing a
      check), that the Dr. you're referring to is the pioneer
      of angiogenesis inhibition for treatment fo cancer.
      This line of work is being exploited commercially by
      several companies, the most notable of which is Entremed,
      which itself is, in my opinion, an excellent long-term
      investment for risk-takers.
      Entermed already has the US
      license for thalidomide as an angiogenesis inhibitor and
      have other NCEs in the pipeline that appear quite
      promising.
      There is no fundamental relationship between tumor
      angiogenesis inhibition and selective viral therapy, except
      that the two would be potentially complementary.
      Onyx's other work, relating to small molecule inhibition
      of oncogenes (like ras) or tumor suppression (via RB
      and APC), or their work with BRCA1 likewise bear no
      direct relationship to angiogensis inhibition.
      These
      other projects are detailed in the recently mailed
      annual statement to investors.

    • I believe (though not positive without doing a
      check), that the Dr. you're referring to is the pioneer
      of angiogenesis inhibition for treatment fo cancer.
      This line of work is being exploited commercially by
      several companies, the most notable of which is Entremed,
      which itself is, in my opinion, an excellent long-term
      investment for risk-takers.
      Entermed already has the US
      license for thalidomide as an angiogenesis inhibitor and
      have other NCEs in the pipeline that appear quite
      promising.
      There is no fundamental relationship between tumor
      angiogenesis inhibition and selective viral therapy, except
      that the two would be potentially complementary.
      Onyx's other work, relating to small molecule inhibition
      of oncogenes (like ras) or tumor suppression (via RB
      and APC), or their work with BRCA1 likewise bear no
      direct relationship to angiogensis inhibition.
      These
      other projects are detailed in the recently mailed
      annual statement to investor's.

    • Thank You. I hate reading through Ed_Atlanta's junk. Even when he has important info, he still sounds ridiculous. Ed please stay off of this BBS.

      Good luck to everyone!!

    • As the thread has become deliberately cluttered with EDs Multiple aliases,(ED IS A SHORT) I offer the following posts providing some actual information about ONXX or the investment position of ACTUAL CONTRIBUTORS 29,30,35,38,45,47,55,56,58,60,65,69,71,73,75,76,80,82,83,85,95,101,106,107,109,112.

    • Thanks for the info. I know a little about this subject and have been reading about it for the last 1 1/2years. How does this relate to the work being done by Judah Folkmann at Harvard?Thanks again.
      JM

    • Yes, I'm an M.D. and a researcher.
      It's difficult to explain briefly and I would refer you to a nice editorial in the June 1997 issue of Nature Medicine, which you can find in any science library for a much more thorough explanation.

      Basically, this is a viral therapy. The virus is a mutant that lacks proteins (called E1B proteins), which normally block a
      human protein called p53 as one of their functions. Now, p53 is important because it (1) is crucially involved in normal human
      cell cycle regulation (a stop dividing signal and also a cell death, or apoptosis, signal), and (2) is mutated and inactive in
      many cancers. Loss of p53 along with other mutation(s) are thought to be responsible for tumorigenesis in many solid cancers
      (including lung, breast, colon, etc.).

      Okay, so this Onyx virus still has its E1A protein which triggers cell cycling (a start signal) but lacks E1B proteins, one of which is resposible for binding to p53 and shutting it off. In a tumor cell with mutant p53 infected with the mutant virus, without E1B, p53 isn't blocked and the cell lyses due to uncontrolled viral replication. Virus is then spread to adjacent tumor cells where the killing goes on.

      It's not as simple as that, of course, but this is the basic idea of how it works. Again, I refer you to the Nature Medicine and other articles on the subject.

      The basic principles involved are sublime and really quite ingenius, which is why I invested in the first place. I'm reasonably convinced that this will be a life-saving therapy, once all of the many "bugs" have been worked out (such how best to deliver, at what dose, for how long, and with what other therapies).

    • View More Messages
 
ONXX
124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.